- Full text PDF available (1)
- This year (3)
- Last 5 years (21)
- Last 10 years (21)
Journals and Conferences
5059Background: Cognitive and mood effects of ABI and ENZA are not well described. An ongoing randomized phase II trial evaluating sequencing of ABI and ENZA in treatment-naive pts with mCRPC (Clin...
Incorporation of docetaxel into metastatic castration-sensitive prostate cancer treatment has added a new treatment option to a disease state that had previously not seen change for decades. Early… (More)
692 Background: Increasing use of subsequent lines of therapy and crossover in phase III randomized clinical trials (P3 RCTs) has shifted how we perceive the effectiveness of treatments for… (More)
INTRODUCTION Radium 223 (Ra223) given for six cycles has proven efficacy in clinical trials, but its population-level generalizability has not been well-described. The objectives of this study were… (More)
INTRODUCTION The treatment landscape of metastatic prostate cancer has changed dramatically over the past five years. As new discoveries are made and further novel therapies become available, there… (More)
BACKGROUND Understanding the drug development pathway is critical for streamlining the development of effective cancer treatments. The objective of the current study was to delineate the drug… (More)
e14518Background: This study evaluated the quality of reporting for Ph0 and WoO trials and impact as measured by citations. Methods: Trials from 1974-2017 were identified using MEDLINE, EMBASE and ...
Introduction Patients with urothelial carcinoma (uc) have a poor prognosis after progression on first-line cisplatin-based chemotherapy. Real-world data about second-line cytotoxic therapies are… (More)